Showing results (71-80 of 99) with videos related to
Sort By:
Pageof 10
Cancer Immunology, Immunotherapy : CII|September 28, 2005
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3Bernd Schlereth, Petra Kleindienst, Iduna Fichtner, et al.Journal of Virology|May 4, 2018
Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody ConstructsJohannes Brozy, Erika Schlaepfer, Christina K S Mueller, et al.Leukemia Research|October 7, 2008
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cellsSandrine d'Argouges, Sandra Wissing, Christian Brandl, et al.Cancer Immunology, Immunotherapy : CII|July 21, 2005
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody constructBernd Schlereth, Cornelia Quadt, Torsten Dreier, et al.Cancer Research|January 4, 2008
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3Maria Amann, Klaus Brischwein, Petra Lutterbuese, et al.Cancer Research|April 5, 2005
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody constructBernd Schlereth, Iduna Fichtner, Grit Lorenczewski, et al.Cancer Cell International|November 4, 2010
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodiesMarkus Münz, Alexander Murr, Majk Kvesic, et al.Plos One|May 11, 2012
The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEALi Peng, Michael D Oberst, Jiaqi Huang, et al.Nature Biotechnology|March 30, 2002
Combined transcriptome and genome analysis of single micrometastatic cellsChristoph A Klein, Stefan Seidl, Karina Petat-Dutter, et al.Molecular Cancer Therapeutics|March 29, 2014
Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemiaMatthias Friedrich, Anja Henn, Tobias Raum, et al.Pageof 10